welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Mayo Clinic Researcher Finds Potential Target to Control Rare Genetic Disease That Strikes in Teen Years
A new study from researchers at Mayo Clinic Center for Individualized Medicine, described in the New England Journal of Medicine, reveals patients with the most severe FAP disease may benefit from a novel combination therapy. The study points to a possible target for intervention and prevention.
Author Niloy Jewel (Jewel) Samadder, M.D., a gastroenterologist and cancer genetics expert at Mayo Clinic’s campus in Ariz., and his colleagues, studied 171 patients with FAP who had various disease stages, at 20 centers in the U.S., Canada and Europe. Researchers evaluated the benefit and safety of the combination of eflornithine and sulindac compared to each drug alone. The investigation represents the largest international phase III FAP trial to date involving pharmaco-prevention — the use of a medication to prevent the need for surgery or other disease progression.
expertly curated content related to this topic
-
Bonnies Diary Feb 08https://jtvcancersupport.com/embed/30453...
-
Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous P...RATIONALE: Chemoprevention is the us...
-
Familial Adenomatous PolyposisFamilial adenomatous polyposis is an inh...
-
Impact of a Hospital-based Register on the Management of Familial Adenomatous PolyposisColorectal cancer in familial adenomatou...
-
Serum Nutrients and Habitual Dietary Intake in Colectomized FAP Patients in NorwayBACKGROUND : Patients with familial aden...
-
Complementary and Alternative Therapies for CancerMany cancer patients use therapies promo...
-
Dietary Polyamine Intake and Risk of Colorectal Adenomatous PolypsBACKGROUND : Putrescine, spermidine, and...